✦ LIBER ✦

Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer

✍ Scribed by Gabriel N. Hortobagyi; Aman U. Buzdar; Debra Frye; Hwee-Yong Yap; Verena Hug; Kavitha Pinnamaneni; Giuseppe Fraschini; H. C. Halvorson; George R. Blumenschein

Publisher: Springer US
Year: 1985
Tongue: English
Weight: 464 KB
Volume: 5
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf01806027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical trial of high-dose oral medroxy

Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature

✍ Enrique Davila; Charles L. Vogel; Dawn East; Victoria Cairns; Susan Hilsenbeck 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 696 KB

Recent studies have suggested that there are benefits from the use of high-dose parenteral medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer. The present study was designed to assess the efficacy and toxicity of high-dose oral MPA in women with clinical parameters sugges

Oral medroxyprogesterone in the treatmen

Oral medroxyprogesterone in the treatment of metastatic breast cancer

✍ Takuma Nemoto; Jashbha1 Patel; Dutzu Rosner; Thomas L. Dao 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

In 47 postmenopausal women with evaluable breast cancer, oral medroxyprogesterone acetate (MPA) was given at a daily dose level of 400 mg. Patients with negative estrogen receptors, poor performance status , or nonresponse to previous endocrine therapy were excluded from this study. There were 25 (

Oral high-dose medroxyprogesterone aceta

Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer

✍ Masaru Izuo; Yuichi Iino; Keiichi Endo 📂 Article 📅 1981 🏛 Springer US 🌐 English ⚖ 510 KB

Pharmacokinetic and pharmacodynamic basi

Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate

✍ Hans Christian Blossey; Hans Erik Wander; Johannes Koebberling; Professor Dr. Ge 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 728 KB

Postmenopausal patients with metastatic breast cancer were treated with medroxyprogesterone acetate (MPA) (Clinovir) in dosages between 500 and 1500 mg orally per day. The relation of MPA plasma concentrations and endocrine effects were studied in a longitudinal fashion. MPA exerted suppressive effe

Adrenal suppression by oral high-dose me

Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients

✍ Henk Veelen; Pax H. B. Willemse; Dirk T. Sleijfer; John J. Pratt; Wim J. Sluiter 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 332 KB

The effects of oral MPA, 300 mg t.i.d., on adrenal function in postmenopausal patients with disseminated breast cancer were evaluated. The levels of serum cortisol, ACTH, androstenedione, DHEA-S, LH, FSH, GH, and prolactin in 22 patients receiving MPA were compared with those in another group of 28

Cyclic and sequential therapy with tamox

Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer

✍ Takuma Nemoto; Dr. Jashbhai K. Patel; Dutzu Rosner; Thomas L. Dao; H. Halvorson 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB

A clinical trial of sequential tamoxifen and medroxyprogesterone acetate (MPA) was carried out in 36 women with metastatic breast cancer in order to evaluate the therapeutic efficacy of this regimen and to determine if tamoxifen would increase progesterone receptor (PR) levels and thereby increase r